Literature DB >> 34406892

Oxidative stress implications for therapeutic vaccine development against Chagas disease.

Subhadip Choudhuri1, Lizette Rios1, Juan Carlos Vázquez-Chagoyán2, Nisha Jain Garg1,3.   

Abstract

INTRODUCTION: Pathogenesis of Chagas disease (CD) caused by the protozoan parasite Trypanosoma cruzi (T. cruzi) involves chronic oxidative and inflammatory stress. In this review, we discuss the research efforts in therapeutic vaccine development to date and the potential challenges imposed by oxidative stress in achieving an efficient therapeutic vaccine against CD. AREAS COVERED: This review covers the immune and nonimmune mechanisms of reactive oxygen species production and immune response patterns during T. cruzi infection in CD. A discussion on immunotherapy development efforts, the efficacy of antigen-based immune therapies against T. cruzi, and the role of antioxidants as adjuvants is discussed to provide promising insights to developing future treatment strategies against CD. EXPERT OPINION: Administration of therapeutic vaccines can be a good option to confront persistent parasitemia in CD by achieving a rapid, short-lived stimulation of type 1 cell-mediated immunity. At the same time, adjunct therapies could play a critical role in the preservation of mitochondrial metabolism and cardiac muscle contractility in CD. We propose combined therapy with antigen-based vaccine and small molecules to control the pathological oxidative insult would be effective in the conservation of cardiac structure and function in CD.

Entities:  

Keywords:  Chagas disease; Trypanosoma cruzi; immunity; oxidative stress; reactive oxygen species; therapeutic vaccine

Mesh:

Substances:

Year:  2021        PMID: 34406892      PMCID: PMC8671175          DOI: 10.1080/14760584.2021.1969230

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  144 in total

1.  Oxidative stress fuels Trypanosoma cruzi infection in mice.

Authors:  Claudia N Paiva; Daniel F Feijó; Fabianno F Dutra; Vitor C Carneiro; Guilherme B Freitas; Letícia S Alves; Jacilene Mesquita; Guilherme B Fortes; Rodrigo T Figueiredo; Heitor S P Souza; Marcelo R Fantappié; Joseli Lannes-Vieira; Marcelo T Bozza
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

2.  Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.

Authors:  Natacha Cerny; Andrés Sánchez Alberti; Augusto E Bivona; Mauricio C De Marzi; Fernanda M Frank; Silvia I Cazorla; Emilio L Malchiodi
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

3.  The substrate specificity of cruzipain 2, a cysteine protease isoform from Trypanosoma cruzi.

Authors:  Flavia C G dos Reis; Wagner A S Júdice; Maria A Juliano; Luiz Juliano; Julio Scharfstein; Ana Paula C de A Lima
Journal:  FEMS Microbiol Lett       Date:  2006-06       Impact factor: 2.742

4.  Increased oxidative stress is correlated with mitochondrial dysfunction in chagasic patients.

Authors:  Jian-jun Wen; Pedro C Yachelini; Adela Sembaj; Rafael E Manzur; Nisha Jain Garg
Journal:  Free Radic Biol Med       Date:  2006-04-26       Impact factor: 7.376

Review 5.  Chagas disease in Europe: A review for the internist in the globalized world.

Authors:  Spinello Antinori; Laura Galimberti; Roberto Bianco; Romualdo Grande; Massimo Galli; Mario Corbellino
Journal:  Eur J Intern Med       Date:  2017-05-11       Impact factor: 4.487

6.  Inhibition of NFE2L2-Antioxidant Response Element Pathway by Mitochondrial Reactive Oxygen Species Contributes to Development of Cardiomyopathy and Left Ventricular Dysfunction in Chagas Disease.

Authors:  Jake Jianjun Wen; Craig Porter; Nisha Jain Garg
Journal:  Antioxid Redox Signal       Date:  2017-07-13       Impact factor: 8.401

Review 7.  Understanding CD8+ T Cell Immunity to Trypanosoma cruzi and How to Improve It.

Authors:  Eva V Acosta Rodríguez; Cintia L Araujo Furlan; Facundo Fiocca Vernengo; Carolina L Montes; Adriana Gruppi
Journal:  Trends Parasitol       Date:  2019-10-10

8.  Trypanosoma cruzi: sequence polymorphism of the gene encoding the Tc52 immunoregulatory-released factor in relation to the phylogenetic diversity of the species.

Authors:  Bruno Oury; Frédérique Tarrieu; Adriano Monte-Alegre; Ali Ouaissi
Journal:  Exp Parasitol       Date:  2005-09-30       Impact factor: 2.011

9.  Specific activation of CD4- CD8- double-negative T cells by Trypanosoma cruzi-derived glycolipids induces a proinflammatory profile associated with cardiomyopathy in Chagas patients.

Authors:  L S A Passos; L M D Magalhães; R P Soares; A F Marques; M do C P Nunes; K J Gollob; W O Dutra
Journal:  Clin Exp Immunol       Date:  2017-07-03       Impact factor: 4.330

10.  Therapeutic Efficacy of a Subunit Vaccine in Controlling Chronic Trypanosoma cruzi Infection and Chagas Disease Is Enhanced by Glutathione Peroxidase Over-Expression.

Authors:  Shivali Gupta; Charity Smith; Sarah Auclair; Anahi De Jesus Delgadillo; Nisha Jain Garg
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.